DLQI (Dermatology Life Quality Index)
Dermatology Life Quality Index (Finlay & Khan 1994): 10 questions about the last week, each scored 0–3, total 0–30. DLQI > 10 = very large effect; with PASI ≥ 10 it defines severe psoriasis for NICE biologic eligibility.
Score interpretation
DLQI 0–1: no effect on the patient's life.
→ Continue topical management; reassure; review at next visit
DLQI 2–5: small effect.
→ Continue topical management; reassure; review at next visit
DLQI 6–10: moderate effect.
→ Consider systemic therapy or phototherapy; psychosocial support; reassess treatment response; dermatology referral if not responding to topicals
DLQI 11–20: very large effect.
→ Psoriasis: DLQI > 10 with PASI ≥ 10 is the NICE definition of severe disease for biologic therapy (when conventional systemic therapy and phototherapy have not worked or are unsuitable); refer to secondary care dermatology; discuss biologic options; assess for comorbidities (psoriatic arthritis, IBD, metabolic syndrome)
DLQI 21–30: extremely large effect.
→ Psoriasis: DLQI > 10 with PASI ≥ 10 is the NICE definition of severe disease for biologic therapy (when conventional systemic therapy and phototherapy have not worked or are unsuitable); refer to secondary care dermatology; discuss biologic options; psychosocial support; assess for comorbidities (psoriatic arthritis, IBD, metabolic syndrome)
Interpretation bands for the DLQI. Apply clinical judgement and local guidance.
References
Related
Curated clinical cross-links plus same-class fallbacks.
- Methotrexate (Dermatology — Psoriasis) · Disease-Modifying Antirheumatic / Immunosuppressant
- Dupilumab · Biologic (IL-4 / IL-13 receptor antagonist)
- Ciclosporin · Systemic Immunosuppressant — Eczema / Psoriasis
- Salicylic Acid · Keratolytic — Warts / Psoriasis / Hyperkeratosis
- Ixekizumab · IL-17A Inhibitor — Psoriasis
- Guselkumab · IL-23 Inhibitor — Psoriasis
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.